nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Biosimilar rhG-CSFs: how similar are they?
|
Gravel, Patricia |
|
2012 |
|
supplement-1 |
p. 3-16 |
artikel |
2 |
Biosimilars: Is absence of proof of difference, proof of absence of difference?
|
Dicato, M. |
|
2011 |
|
supplement-1 |
p. 1-2 |
artikel |
3 |
Colony stimulating factors (CSF) biosimilars. Progress?
|
Scotté, Florian |
|
2012 |
|
supplement-1 |
p. 17-24 |
artikel |
4 |
Erythropoietin biosimilars currently available in hematology-oncology
|
Kamioner, Didier |
|
2012 |
|
supplement-1 |
p. 25-28 |
artikel |
5 |
Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?
|
Drouet, Ludovic |
|
2012 |
|
supplement-1 |
p. 35-42 |
artikel |
6 |
Presently available biosimilars in hematology-oncology: G-CSF
|
Gascon, Pere |
|
2012 |
|
supplement-1 |
p. 29-34 |
artikel |
7 |
Risk management of biosimilars in oncology: each medicine is a work in progress
|
Vulto, Arnold G. |
|
2012 |
|
supplement-1 |
p. 43-49 |
artikel |
8 |
The economic pressures for biosimilar drug use in cancer medicine
|
Cornes, Paul |
|
2012 |
|
supplement-1 |
p. 57-67 |
artikel |
9 |
What do prescribers think of biosimilars?
|
Aapro, M. S. |
|
2011 |
|
supplement-1 |
p. 51-55 |
artikel |